
Loading, please wait...

Loading, please wait...

Alzheimer's disease (AD) remains one of the most challenging neurodegenerative conditions worldwide, characterized by progressive cognitive decline. Recent research has highlighted that cerebral glucose hypometabolism is a core feature of AD, occurring well before clinical symptoms manifest. Consequently, modulating brain energy metabolism has emerged as a promising therapeutic strategy. New experimental evidence suggests that Electroacupuncture for Alzheimer's may play a vital role in restoring these metabolic functions and improving cognitive outcomes.
In a recent study using 5×FAD mouse models, researchers demonstrated that electroacupuncture (EA) treatment significantly improves learning and memory. The therapy specifically targets the hippocampus, a brain region critical for memory formation. By reducing β-amyloid (Aβ) deposition and enhancing metabolic efficiency, EA provides a multi-faceted approach to neuroprotection. However, the most striking finding involves the specific molecular pathways that govern these metabolic improvements.
The study revealed that EA specifically activates the IGF1/IGF1R signaling pathway within the hippocampus. This activation is crucial because it promotes the membrane translocation of GLUT3, the primary glucose transporter in neurons. Consequently, enhanced neuronal glucose uptake provides the necessary fuel for cellular functions. Furthermore, this metabolic boost increases the activity of the tricarboxylic acid (TCA) cycle, which is the powerhouse of cellular energy production. Therefore, the improved energy supply directly supports synaptic plasticity and cognitive resilience.
Additionally, the research highlighted that EA helps optimize information processing within the brain's metabolic network. By enhancing glucose metabolism, the treatment effectively mitigates the "energy crisis" typically seen in AD brains. This restoration of metabolic health not only slows the progression of memory deficits but also offers a biological basis for using acupuncture as a complementary clinical tool.
While the current findings are based on animal models, they provide strong theoretical and experimental support for the clinical application of EA. In practice, physicians might consider electroacupuncture as part of a holistic management plan for geriatric patients. Moreover, the safety profile and non-invasive nature of EA make it an attractive adjunct to standard pharmacological treatments like cholinesterase inhibitors. However, further large-scale human trials are necessary to standardize protocols and confirm long-term efficacy in diverse patient populations.
Electroacupuncture enhances glucose metabolism by activating specific signaling pathways like IGF1/IGF1R. This process increases the translocation of glucose transporters (GLUT3) to the neuronal membrane, allowing the brain to utilize energy more efficiently.
Yes, experimental studies have shown that consistent electroacupuncture treatment can significantly attenuate the deposition of β-amyloid (Aβ) in the hippocampus and cortex, which are hallmark features of Alzheimer's disease.
Electroacupuncture is generally considered safe and well-tolerated when performed by trained professionals. It is a non-pharmacological intervention that can be used alongside standard medications to help manage cognitive symptoms.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Liang S et al. Electroacupuncture Improves the Learning and Memory by Modulating Hippocampal Glucose Metabolism through IGF1/IGF1R Signaling in Alzheimer's Disease. Adv Sci (Weinh). 2026 May 23. doi: 10.1002/advs.202514241. PMID: 42175737.
Li R, Chen Z, Jiang Y, et al. Electroacupuncture for treating the cognitive symptoms of Alzheimer's disease: a randomized controlled trial. Front Psychiatry. 2026;17:1834514. doi: 10.3389/fpsyt.2026.1834514.
Xu A, et al. Electroacupuncture Protects Cognition by Regulating Tau Phosphorylation and Glucose Metabolism via the AKT/GSK3β Signaling Pathway in Alzheimer's Disease Model Mice. Frontiers in Neuroscience. 2020;14:387-400. doi: 10.3389/fnins.2020.574023.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study reveals electroacupuncture improves memory in Alzheimer's by modulating hippocampal glucose metabolism through the IGF1/IGF1R signaling pathway....
3 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today